Join Growin Stock Community!

雅祥生醫6652.TW Overview

TW StockBiotech. & Medical
(No presentation for 6652)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

雅祥生醫（6652）Overall Performance

雅祥生醫（6652）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

雅祥生醫（6652） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

雅祥生醫（6652）Key Information

雅祥生醫（6652）Profile

Eusol Biotech Co.,Ltd. focuses on research and development of new biotech drugs for sleep disorders. Its pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for repairing neuron function; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with sedative effect. The company was founded in 1994 and is headquartered in Taipei, Taiwan.

雅祥生醫（6652）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.65
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2277.16
PB Ratio
2.42
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
52.70%
Net Margin
-24160.27%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.65
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2277.16
PB Ratio
2.42
Price-to-FCF
-
Gross Margin
52.70%
Net Margin
-24160.27%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
default symbol

6652

雅祥生醫

6.15D

-10.41%

(-0.10)

  • When is 6652's latest earnings report released?

    The most recent financial report for 雅祥生醫 (6652) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6652's short-term business performance and financial health. For the latest updates on 6652's earnings releases, visit this page regularly.

  • How much cash does 6652 have?

    At the end of the period, 雅祥生醫 (6652) held Total Cash and Cash Equivalents of 193.18M, accounting for 0.54 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6652 go with three margins increasing?

    In the latest report, 雅祥生醫 (6652) did not achieve the “three margins increasing” benchmark, with a gross margin of 52.7%%, operating margin of -6,690.54%%, and net margin of -6,204.86%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6652's profit trajectory and future growth potential.